Abaloparatide
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Abaloparatide and local guidelines before prescribing.
Anabolic bone agent
Mechanism
PTHrP analogue (anabolic).
Uses
Severe postmenopausal osteoporosis.
Dosing
- Abaloparatide | 80 micrograms SC daily for up to 18 months. Postmenopausal women at very high risk (NICE TA991). Follow with an antiresorptive.
Endocrinology: Bone Medicine
Side effects
Dizziness, palpitations, hypercalcaemia, injection-site reactions.
Interactions
Few.
Contraindications and cautions
Hypercalcaemia, Paget disease
Monitoring
Calcium
Pregnancy and breastfeeding
Not for use
Renal and hepatic impairment
Avoid in severe renal impairment
Overdose and reversal
Supportive
Special advice
Maximum 18 months; follow with antiresorptive.
More from the textbook: uses, cautions and other points
- Anabolic: Stimulate osteoblasts to build new bone - teriparatide, abaloparatide, romosozumab. These produce bigger, faster gains.
Endocrinology: Bone Medicine - Anabolic courses: Fixed duration (teriparatide 24 months, abaloparatide 18 months, romosozumab 12 months), always followed by antiresorptive treatment.
Endocrinology: Bone Medicine - Very high risk: anabolic first (teriparatide, abaloparatide, romosozumab), always followed by an antiresorptive.
Endocrinology: Bone Medicine - NICE TA991: Abaloparatide for osteoporosis after menopause
Endocrinology: Bone Medicine
Where it is discussed in the book
- Endocrinology: Bone Medicine (5 mentions)